BIOLOGY.DIGITAL
A CD7-targeted AAV variant enables efficient T and NK cell engineering in vivo

Image: Nature Biotechnology

Research

A CD7-targeted AAV variant enables efficient T and NK cell engineering in vivo

November 17, 2026 • Source: Nature Biotechnology

A CD7-targeted AAV variant enables efficient T and NK cell engineering in vivo

**Weekly Intelligence Dispatch (2026-11-17):** A CD7-targeted AAV variant enables efficient T and NK cell engineering in vivo (Source: Nature Biotechnology).

Technical & Enterprise R&D Implications

A CD7-targeted AAV variant enables efficient T and NK cell engineering in vivo Enterprise buyers and technical leads tracking Research can verify full primary documentation via Nature Biotechnology.

Published November 17, 2026

More News

Last updated: November 17, 2026

Ask AI